AstraZeneca's ENHERTU Gains FDA Nod for Two New Early Breast Cancer Indications
Event summary
- AstraZeneca and Daiichi Sankyo's ENHERTU received FDA approval for two new indications in HER2-positive early breast cancer.
- The approvals are based on results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials.
- ENHERTU demonstrated a 11.2% improvement in pathologic complete response (pCR) rate compared to standard treatment in the neoadjuvant setting.
- In the adjuvant setting, ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to trastuzumab emtansine (T-DM1).
- AstraZeneca will pay Daiichi Sankyo $155 million in milestone payments following the approvals.
The big picture
The FDA approvals for ENHERTU mark a significant milestone in the treatment of HER2-positive early breast cancer, positioning the drug as a potential new standard of care. This expansion into the early breast cancer market comes as AstraZeneca and Daiichi Sankyo aim to broaden ENHERTU's clinical utility beyond metastatic settings. The approvals underscore the growing importance of antibody-drug conjugates (ADCs) in oncology, with ENHERTU emerging as a key player in this rapidly evolving therapeutic class.
What we're watching
- Market Expansion
- Whether AstraZeneca can leverage these approvals to expand ENHERTU's market share in early breast cancer treatment.
- Regulatory Momentum
- The pace at which other regulatory agencies approve ENHERTU for these new indications.
- Commercial Execution
- How effectively AstraZeneca and Daiichi Sankyo can commercialize ENHERTU in the competitive early breast cancer market.
Related topics